Tag:
Idera Pharmaceuticals
Latest Headlines
Latest Headlines
Idera's troubled TLR program founders in PhII cancer study
This morning the biotech highlighted just how problematic the field is when it announced that the lead drug in that pact--IMO-2055--failed a mid-stage study in advanced head and neck cancer.
UPDATED: Idera gets FDA green light for Phase II psoriasis drug test
Idera Pharmaceuticals ( $IDRA ) is ending the week with a second piece of positive news. The Cambridge, MA-based drug developer disclosed Dec. 1 that the FDA has reversed a clinical hold on IMO-3100,
Merck KGaA nixes development of Idera Pharma cancer drug
Idera Pharmaceuticals' advancement of a Toll-like receptor agonist against cancer has taken a blow. Partner Merck KGaA has informed the developer ( $IDRA ) that the German pharma is ending development
Former Idera chief hunts money to back biotech startup
Stephen Seiler, the former CEO at Idera Pharmaceuticals, is out making the rounds to raise funds for a new biotech startup. Seiler tells Xconomy that he hopes to raise $10 million for a Series A to
